Rate My Professor Patrick Green

Green's laboratory is internationally recognized for pioneering contributions to the molecular mechanisms underlying T-lymphocyte transformation, leukemia/lymphoma induction, and neurological disease by human T-cell leukemia viruses (HTLV-1 and HTLV-2). His research encompasses viral and cellular regulators of HTLV gene expression, replication, cellular transformation, and viral persistence, with key projects investigating the HTLV-1 accessory protein Hbz's roles in replication, cell survival, proliferation, and tumorigenesis; the arginine methyltransferase PRMT5's function in HTLV-driven transformation and as a therapeutic target; and comparative analyses of HTLV antisense proteins. He has secured sustained NIH/NCI funding as principal investigator of the "Retrovirus Models of Cancer" Program Project Grant, renewed for its fifth cycle through 2025. Green has garnered major awards including the 2025 Distinguished University Professor honor, Ohio State University Distinguished Scholar, Fellow of the American Association for the Advancement of Science and American Academy of Microbiology, Dale McFarlin Award, Inaugural David Derse Memorial Lecture/Award, and International Retrovirology Association Award for Exceptional Contribution. His scholarly output exceeds 160 publications, with recent highlights such as "Role of the CTCF Binding Site in Human T-Cell Leukemia Virus-1 Pathogenesis" (PLoS Pathogens, 2025), "Vulnerability to APOBEC3G is linked with pathogenesis of deltaretroviruses" (PNAS, 2024), "An HTLV-1 envelope mRNA vaccine is immunogenic and protective in New Zealand rabbits" (J Virol, 2024), and "The PRMT5 inhibitor EPZ015666 selectively targets HTLV-1-transformed T-cell lines in vitro and in vivo" (Front Microbiol, 2023). He has mentored over 50 trainees and contributes editorially to journals like AIDS Research and Human Retroviruses.